Gabapentin Capsule
Product Images NDC 70518-4746

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-4746). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (02ae9973 70b1 4bcb A7aa E48351906e74 01)

An illustration depicting the formula for calculating creatinine clearance (CLCr) using age, weight, and serum creatinine, with an adjustment factor for female patients. The formula is a clinical calculation aid, shown with variables for age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Figure1 (02ae9973 70b1 4bcb A7aa E48351906e74 02)

Chemical structure of gabapentin showing a cyclohexane ring attached to a central carbon bonded to an amino group and a carboxylic acid group.*

FDA Label Image

Image 1 (02ae9973 70b1 4bcb A7aa E48351906e74 03)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to week 8. The y-axis shows the mean pain score ranging from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain score for Gabapentin compared to relatively stable scores for placebo.*

FDA Label Image

Image 2 (02ae9973 70b1 4bcb A7aa E48351906e74 04)

Line graph depicting mean pain scores over 7 weeks for placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day groups. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period, showing pain scores decreasing more in gabapentin groups compared to placebo.*

FDA Label Image

Image 3 (02ae9973 70b1 4bcb A7aa E48351906e74 05)

A bar chart titled 'Figure 3. Proportion of Responders (patients with a 50% reduction in pain score) at Endpoint: Completed PHN Studies.' It compares the percentage of responders between placebo (PBO) and different doses of gabapentin (GBP 3600 in Study 1; GBP 1800 and GBP 2400 in Study 2). Values range from 0% to 100% on the vertical axis.*

FDA Label Image

Image 4 (02ae9973 70b1 4bcb A7aa E48351906e74 06)

A scatter plot showing the percentage difference on the y-axis against daily dose (mg) on the x-axis. Data points represent three studies labeled a, b, and c, with different daily doses ranging from 600 mg to 1800 mg and corresponding difference percentages from about 5% to 18%.*

FDA Label Image

Mm2 (Gabapentin 300mg 70518 4746 01)

Gabapentin Capsule, 300 mg strength, in a package containing 30 capsules. The capsule color is yellow/brown. The label shows the NDC number 70518-4746-01 and indicates the product is repackaged by RemedyRepack Inc., Indiana, PA. The manufacturer listed is Strides Pharma Inc., East Brunswick, NJ. Storage instructions and a QR code are also visible.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin Capsule 300 mg oral capsules, bottle label showing quantity of 30 capsules, repackaged by RemedyRepack Inc. The label includes NDC 70518-4746-00 and describes the capsule color as yellow and brown. Manufacturer is Strides Pharma Inc., East Brunswick, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.